Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Subject: search.filters.subject.rare

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    History of the Rare Cancer Network and past research
    (PAGEPRESS PUBL, 2014-01-01) Mirimanoff, Rene-Olivier; Ozsahin, Mahmut; Thariat, Juliette; Ozyar, Enis; Schick, Ulrike; Pehlivan, Berrin; Krengli, Marco; Pellanda, Alessandra Franzetti; Vees, Hansjoerg; Cai, Ling; Scandolaro, Luciano; Belkacemi, Yazid; Villa, Salvador; Igdem, Sefik; Lutsyk, Myroslav; Miller, Robert C.
    Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN.
  • Thumbnail Image
    Item
    The Rare Cancer Network: ongoing studies and future strategy
    (SAGE PUBLICATIONS LTD, 2014-01-01) Ozsahin, Mahmut; Mirimanoff, Rene-Olivier; Thariat, Juliette; Sun, Xu Shan; Atalar, Banu; Lassen-Ramshad, Yasmin; Ugurluer, Gamze; Krishnan, Sunil; Hallemeier, Christopher; Van Houtte, Paul; Krengli, Marco; Zhang, Lan Jun; Chang, Kenneth; Funk, Ryan; Rooney, Jessica; Miller, Robert C.
    The Rare Cancer Network (RCN) was formed in the early 1990's to create a global network that could pool knowledge and resources in the studies of rare malignancies whose infrequency prevented both their study with prospective clinical trials. To date, the RCN has initiated 74 studies resulting in 46 peer reviewed publications. The First International Symposium of the Rare Cancer Network took place in Nice in March of 2014. Status updates and proposals for new studies were heard for fifteen topics. Ongoing studies continue for cardiac sarcomas, thyroid cancers, glomus tumors, and adult medulloblastomas. New proposals were presented at the symposium for primary hepatic lymphoma, solitary fibrous tumors, Rosai-Dorfman disease, tumors of the ampulla of Vater, salivary gland tumors, anorectal melanoma, midline nuclear protein in testes carcinoma, pulmonary lymphoepithelioma-like carcinoma, adenoid cystic carcinoma of the trachea, osteosarcomas of the mandible, and extra-cranial hemangiopericytoma. This manuscript presents the abstracts of those proposals and updates on ongoing studies, as well a brief summary of the vision and future of the RCN.
  • Thumbnail Image
    Item
    A Rare Confusing Nevus Variant: Meyerson Nevus
    (AVES, 2018-01-01) Yildiz, Pelin; Kucuk, Ozlem Su; Tosuner, Zeynep; Arici, Belfin Nur; Dizman, Didem; Deveci, Ugur; Demirkesen, Cuyan
    Meyerson nevus is a rare benign entity described by Meyerson et al in 1971 as a melanocytic nevus surrounded by inflammatory, eczematous eruption that resolves spontaneously or by topical steriod therapy (fluticasone propionate, Abdi Ibrahim Ilac San. ve Tic. A.S., Istanbul), but the nevus persists. This entity is not well known and there is limited information in the literature. Since the lesion may develop suspicion for malignancy, it is important to keep this entity in mind. In this article we present three Meyerson nevi, two of which belong to one patient.